ClinicalTrials.gg
CompletedNCT02516293Updated Aug 5, 2015

Cardiac Rehabilitation in Chagas Heart Failure

A Phase 2/3 interventional study of Exercise, nutritional and pharmaceutical counseling in Chagas Disease and Chagas Cardiomyopathy, sponsored by Evandro Chagas National Institute of Infectious Disease. Completed at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-05.

Primary conditionChagas CardiomyopathyRegistry: Chagas DiseaseReclassifiedWhy we changed it
Registry
Chagas Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chagas Cardiomyopathy
Why
  1. The study's listed conditions name Chagas Cardiomyopathy, a narrower term within Chagas Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Evandro Chagas National Institute of Infectious Disease · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Chagas Cardiomyopathy with a site in Brazil — 2 open to participants now, 2 under way, 1 of them phase 3. Chagas Cardiomyopathy · Brazil.

Enrollment
11th of 11
12 · median 42
Started
2013
with 1 other
Phase 2/3
Only one
of the 14
Registered
8th of 14
by date
Lead sponsor
2 of 14
Evandro Chagas National Institute of Infectious Disease

Among the 14 studies in Chagas Cardiomyopathy with a site in Brazil, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2013, is the only one in phase 2/3, and was the 8th registered.

Chagas Cardiomyopathy

17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.

Browse Chagas Cardiomyopathy studies →

Open to participants now

2 of the 14 studies in Chagas Cardiomyopathy with a site in Brazil are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2 Chagas Cardiomyopathy studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Chagas Cardiomyopathy with a site in Brazil, or all of them as a file.
02

Study summary

Due to the lack of information in the literature about the role of cardiac rehabilitation on Chagas heart failure, the aim of the present study was to evaluate the effects of a cardiac exercise program on functional capacity, cardiac function, respiratory muscle strength, body composition, biomarkers and quality of life among Chagas heart failure patients.

Read the detailed description

The present study consisted in a pre/post single-arm intervention study conducted at the Evandro Chagas National Institute of Infectious Disease (INI), located on Rio de Janeiro, Brazil. INI is a national reference center for treatment and research in infectious diseases and tropical medicine in Brazil, which follows a large cohort of patients with Chagas disease, all of them diagnosed by two simultaneously positive serological tests (enzyme-linked immunosorbent assay and indirect immunofluorescence). Patients included in the study were submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during an 8-month period. Nutritional and pharmaceutical counseling were also monthly provided during the follow-up and consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.Patients included in the study were followed during an 8-month period in which evaluations of functional capacity (maximal progressive cardiopulmonary exercise test), muscle respiratory strength (manovacuometry) and body composition (anthropometry and skinfolds) were performed at baseline, after four months and at the end of follow-up. Assessments of cardiac function (bidimensional echocardiography), biomarkers (lipid profile, glucose and glycated hemoglobin) and quality of life (Minnesota Living with Heart Failure questionnaire) were taken at baseline and after eight months of follow-up.

03

Conditions studied

  • Chagas Disease
  • Chagas Cardiomyopathy

Browse trials for

04

In context

Chagas Cardiomyopathy Reclassified

17 studies on the registry are indexed under Chagas Cardiomyopathy; 2 are open to participants now.

This study's enrollment of 12 is below the median of 45 across 13 interventional studies indexed under Chagas Cardiomyopathy.

Browse Chagas Cardiomyopathy studies →

Lead sponsor

Evandro Chagas National Institute of Infectious Disease is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Chagas Cardiomyopathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Chagas Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients at the stages C or D of Chagas cardiomyopathy
  • Patients receiving standard optimized medical therapy
  • Patients with good adherence to outpatient treatment within the last three months.

Exclusion criteria

Exclusion Criteria:

  • Those who were not able to attend three weekly training sessions,
  • Those who had neuromuscular limitations, cardiopathies from non-Chagasic etiology (e.g ischemic), systemic conditions that limits exercise practice (e.g )
  • Practitioners of regular exercise.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Intervention group

    * Physical exercise intervention * Nutritional counseling * Pharmaceutical counseling

    Behavioral: Exercise, nutritional and pharmaceutical counseling

Interventions

  • BehavioralExercise, nutritional and pharmaceutical counseling

    Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.

07

What researchers measure

Primary outcomes

  1. Functional Capacity (VO2 max)

    VO2 max (ml/kg/min)

    Time frame: Change from baseline at 4 and 8 months

Secondary outcomes

  1. Muscle respiratory strength (maximal inspiratory pressure and maximal expiratory pressure)

    Maximal inspiratory pressure and maximal expiratory pressure (cm H2O)

    Time frame: Change from baseline at 4 and 8 months

  2. Body composition (body fat percentage)

    Body fat percentage (%)

    Time frame: Change from baseline at 4 and 8 months

  3. Cardiac function (mainly ejection fraction)

    Ejection fraction (%)

    Time frame: Change from baseline at 8 months

  4. Biomarkers (lipid profile and glucose)

    Total cholesterol, Triacylglycerol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol (mg/dl) and glucose (mg/dl)

    Time frame: Change from baseline at 8 months

  5. Biomarkers (glycated hemoglobin)

    Glycated hemoglobin (%)

    Time frame: Change from baseline at 8 months

  6. Quality of life by Minnesota Living with heart failure questionnaire (MLHFQ)

    MLHFQ Score ranging from 0 to 105

    Time frame: Change from baseline at 8 months

  7. Anthropometry

    Body weight (kg)

    Time frame: Change from baseline at 4 and 8 months

  8. Anthropometry

    Waist and hip circumference (cm)

    Time frame: Change from baseline at 4 and 8 months

08

Study locations

1 site
  • Evandro Chagas National Institute of Infectious Disease
    Rio de Janeiro, RJ 21040-360, Brazil
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Jan 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2015
First posted
Aug 5, 2015
Start
May 2013
Primary completionActual
Jan 2014
CompletionActual
Dec 2014
Last update
Aug 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02516293
Lead sponsor
Evandro Chagas National Institute of Infectious Disease
Responsible party
Mauro Felippe Felix Mediano (Clinical Researcher in Public Health, Evandro Chagas National Institute of Infectious Disease) — Principal investigator
First posted
Aug 5, 2015
Start date
May 2013
Primary completion
Jan 2014
Completion
Dec 2014
Last update
Aug 5, 2015

Study contacts

Andrea S Sousa, PhD
principal investigator · Evandro Chagas National Institute of Infectious Disease

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion